鈉-葡萄糖共轉(zhuǎn)運(yùn)蛋白2(SGLT2)抑制劑是一類新興的治療糖尿病的藥物.近年來(lái),遺傳學(xué)和藥理學(xué)研究發(fā)現(xiàn),胃腸道SGLT1蛋白也可能成為一個(gè)有治療前景的藥物靶點(diǎn).SGLT1/SGLT2雙靶點(diǎn)抑制劑的開(kāi)發(fā)將為糖尿病的治療提供另一個(gè)非胰島素依賴的途徑.臨床研究表明,sotagliflozin可以通過(guò)雙重抑制SGLT1和SGLT2的作用來(lái)降低餐后血糖、升高GLP-1和促進(jìn)尿糖排出.因此,這些特征使得sotagliflozin在對(duì)1型和2型糖尿病的治療方面具有重要臨床意義.

The sodium-dependent glucose transporter 2 (SGLT2) inhibitors is an important emerging class for the treatment of diabetes. In recent years, genetic and pharmacology researches have indicated that gastrointestinal SGLT1 inhibitors may also be an appropriate therapeutic target to treat diabetes. Combining SGLT1 and SGLT2 inhibitors in a single molecule would provide complementary insulin-independent mechanisms to treat diabetes. Therefore, sotagliflozin has been developed as a dual inhibitor of SGLT1 and SGLT2. The differentiating clinical features of dual inhibitor of SGLT1 and SGLT2 include a large postprandial glucose reduction, elevation of glucagon-like peptide 1 and modest urinary glucose excretion. These features may have clinical implications for the use of sotagliflozin in the treatment of both type 1 and type 2 diabetes.

天津市應(yīng)用基礎(chǔ)與前沿技術(shù)研究計(jì)劃項(xiàng)目(14JCZDJC33500)